Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
News
Investors
Careers
Contact
locationPlaceholder
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
News
Investors
Careers
Contact
Show Search
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
283 Results
283 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Oncology
European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
December 30, 2024
Belgium
Read more
Immunology
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis
The Company is licensing a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune and allergic diseases
The agreement bolsters Johnson & Johnson’s commitment to addressing disease-relevant pathways across patient types through novel mechanisms and modalities to transform the treatment of atopic dermatitis as well as other autoimmune and allergic diseases
December 26, 2024
Read more
Oncology
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
December 18, 2024
Belgium
Read more
Oncology
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
December 9, 2024
United States
Read more
Immunology
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
December 9, 2024
United States
Read more
Oncology
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
December 8, 2024
United States
Read more
Oncology
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
December 8, 2024
United States
Read more
Oncology
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
December 8, 2024
United States
Read more
Immunology
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
December 2, 2024
United States
Read more
Immunology
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
November 22, 2024
United States
Read more
Previous
6 of 29
Next
Featured stories
Connecting the best of Health&Care
Read more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Read more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Read more
What is a gene mutation?
Read more
